Skip to main content
main-content

Canagliflozin

News

18-09-2019 | Semaglutide | EASD 2019 | News

SUSTAIN 8: Semaglutide outperforms canagliflozin as second-line therapy for type 2 diabetes

Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.

09-09-2019 | Nephropathy | News

Meta-analysis supports use of SGLT2 inhibitors to prevent kidney failure

Findings from a systematic review and meta-analysis suggest that SGLT2 inhibitors reduce the risk for major adverse kidney outcomes among people with type 2 diabetes, regardless of baseline kidney function.

23-08-2019 | Canagliflozin | Highlight | News

CANVAS canagliflozin fracture effect may be chance finding

A comparison of CANVAS and CANVAS-R fails to detect any potential explanation for the increased fracture risk seen with canagliflozin versus placebo in the former trial.

Read more

Opinion

22-11-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

In depth

22-08-2017 | Canagliflozin | Podcast | Article

Dissecting the CANVAS trial

In this podcast, CANVAS investigators Carol Wysham and Lori Berard discuss the implications of the program's findings for healthcare professionals treating patients with diabetes (11:17).

Journal articles and book chapters

05-09-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

23-07-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

23-06-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

Case reports

Image Credits